Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

BACKGROUND: Multiple myeloma is an incurable haematological malignancy that is associated with a high probability of relapse. The survival of relapsed patients has been greatly improved by the development of novel drugs such as lenalidomide and bortezomib. We assessed the cost-effectiveness of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsela, Lineo Marie, Cleary, Susan, Wilkinson, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746097/
https://www.ncbi.nlm.nih.gov/pubmed/36510230
http://dx.doi.org/10.1186/s12962-022-00399-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746097/
https://www.ncbi.nlm.nih.gov/pubmed/36510230
http://dx.doi.org/10.1186/s12962-022-00399-4

Ejemplares similares